Sign In
Buy ZLAB
$17.17
+0.0200 (+0.117%)
At Close: Jun 03, 2026
Zai Lab Announces Proposed Public Offering of American Depositary Shares
04:05pm, Monday, 19'th Apr 2021
SHANGHAI and SAN FRANCISCO, April 19, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company,
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
07:37am, Tuesday, 13'th Apr 2021
Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
04:57am, Wednesday, 31'st Mar 2021
China NMPA approval follows 2020 U.S. FDA approval for the treatment of patients with fourth-line GIST
7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines
11:54am, Friday, 12'th Mar 2021
If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Co
Zai Lab Limited (ZLAB) CEO Samantha Du on Q4 2020 Results - Earnings Call Transcript
01:39pm, Monday, 01'st Mar 2021
Zai Lab Limited (ZLAB) CEO Samantha Du on Q4 2020 Results - Earnings Call Transcript
Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021
07:31am, Thursday, 18'th Feb 2021
Company to Host Conference Call and Webcast on March 1, 2021 at 8:00 a.m. ET Company to Host Conference Call and Webcast on March 1, 2021 at 8:00 a.m. ET
Zai Lab Announces Upcoming Presentations in February Investor Conferences
07:30am, Thursday, 28'th Jan 2021
SHANGHAI and SAN FRANCISCO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that senior manageme
Turning Point and Zai Lab Broaden Collaboration
06:45am, Monday, 11'th Jan 2021
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point's MET/SRC/CSF1R Inhibitor, in Greater China
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs
03:16pm, Sunday, 10'th Jan 2021
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
04:01pm, Wednesday, 06'th Jan 2021
Regulated Information/Inside Information
Week In Review: DXY Raises $500 Million For Online Consumer Healthcare Site
03:08pm, Sunday, 03'rd Jan 2021
Week In Review: DXY Raises $500 Million For Online Consumer Healthcare Site
These Were the 5 Best Medical Device Stocks of 2020
10:07am, Thursday, 31'st Dec 2020
These companies made millions by developing equipment for life-saving care, and enriched shareholders too.
Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference
07:30am, Wednesday, 30'th Dec 2020
SHANGHAI and SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China's National Reimbursement Drug List
07:00pm, Monday, 28'th Dec 2020
SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has be
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
07:30am, Monday, 28'th Dec 2020
- Zai Lab to lead development and commercialization of CLN-081 in Greater China
